Hunting for upside potential typically reserved for the private equity world? Look no further.
The company expects to announce a new CFO “in the coming months.”
Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.
Biotech stocks have been outperforming the broader market over the past three months, driven by optimism regarding potential rate cuts. The Fed is expected to start cutting rates later this month, and...